Development of a Procedure for Identification of Biperiden Hydrochloride with Specificity for Triperiden Hydrochloride

N. E. Kuz’mina; S. V. Moiseev; V. I. Krylov; A. A. Kutin; V. A. Yashkir; V. A. Merkulov

doi:10.1007/s11094-018-1749-x

Development of a Procedure for Identification of Biperiden Hydrochloride with Specificity for Triperiden Hydrochloride

Autores: Kuz’mina N.E.¹, Moiseev S.V.¹, Krylov V.I.¹, Kutin A.A.¹, Yashkir V.A.¹, Merkulov V.A.¹
Afiliações:
1. Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation
Edição: Volume 51, Nº 12 (2018)
Páginas: 1106-1110
Seção: Article
URL: https://ogarev-online.ru/0091-150X/article/view/244931
DOI: https://doi.org/10.1007/s11094-018-1749-x
ID: 244931

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

Biperiden hydrochloride, (1RS)-1-[(1RS, 2SR, 4RS)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl-3-(piperidin-1-yl)prop an-1-ol hydrochloride, is one of the most efficacious cholinolytics. It is used to treat Parkinson’s disease and various types of muscular spasms and to ameliorate uncoordinated muscular movements that can accompany the use of several tranquilizers [1, 2]. Biperiden appears in the vital and essential drug list that was approved by an order of the RF Government [3].